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pravastatin sodium (PVS) in pure and pharmaceutical formulations has been described. Themethod is
based on the formation of colored product between PVS and 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole
(NBD-Cl) in acetone medium at 55 ± 2 C. The reaction is followed spectrophotometrically by mea-
suring the increase in absorbance at 462 nm as a function of time. The initial rate and ﬁxed timemeth-
ods were adopted for constructing the calibration curves. The linearity ranges were found to be 15.0–
50.0 and 10.0–70.0 lg mL1 for initial rate and ﬁxed time methods, respectively. The limits of detec-
tion for initial rate and ﬁxed time methods are 0.029 and 0.086 lg mL1, respectively. Both methods
have been applied successfully for the estimation of PVS in commercial dosage forms with no interfer-
ence from the excipients. The results are compared with the HPLC pharmacopoeial method.
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lsevier1. Introduction
Pravastatin is hexahydro-6-hydroxy-2-methyl-8-(2-methylbu-
tyryloxy)-1-naphthyl-3,5-dihydroxyheptanoate, is one of a
class of lipid-lowering compounds, the HMG-CoA reductase
inhibitors, which reduce cholesterol biosynthesis. These com-
pounds are used for the treatment of hypercholesterolemia.
Pravastatin is characterized as one of the best, due to the hy-
droxyl group attached to its decal in ring, which results in a
greater hydrophilicity than other HMG-CoA reductase inhib-
itors (Lennerna¨s and Fager, 1997; Hatanaka, 2000; Haria and
McTavish, 1997).
Literature survey reveals that pravastatin is ofﬁcial in B.P.
(British Pharmacopoeia, 2007). Several analytical methods are
300 S. Ashour, M. Khateebavailable for the determination of the latter compound in
pharmaceutical dosage forms, these include spectrophotomet-
ric method based on the reduction of ferric to ferrous ions
followed by complexation with 2,20-bipyridyl or 1,10-phenan-
throline to produce orange red chromogen (Kalvikkarasi
et al., 2009), high performance liquid chromatography (HPLC)
with ultraviolet detector (Onal and Sagirli, 2006; Pasha et al.,
2006; Ashour et al., 2008; Campos-Lara and Mendoza-Espi-
noza, 2008; Gomes et al., 2009), capillary electrophoresis (Kir-
cali et al., 2004; Nigovic and Vegar, 2008), high performance
liquid chromatography and capillary electrophoresis (Kocijan
et al., 2005), high performance thin layer chromatography
(Chaudhari et al., 2007), electroanalytical methods by
square-wave adsorptive-stripping voltammetry (Nigovic,
2006), and differential plus polarography (Coskun et al.,
1997). Pravastatin has been determined in biological samples
by HPLC with laser-induced ﬂuorescence detector (Dumous-
seaux et al., 1994) and ultraviolet detector (Iacona et al.,
1994; Whigan et al., 1989; Bauer et al., 2005; Siekmeier
et al., 2000; Otter and Mignat, 1998), liquid chromatogra-
phy/tandem mass spectrometry (LC/MS/MS) (Zhu and Neir-
inck, 2003; Jemal et al., 1998; Mulvana et al., 2000), liquid
chromatography/atmospheric-pressure chemical ionization
mass spectrometry (LC/APCIMS) (Kawabata et al., 1998),
and gas chromatography employing chemical ionization mass
spectrometry (GC/CIMS) (Morris et al., 1993; Funke et al.,
1989; Cai et al., 1996).
Kinetic methods have certain advantages in pharmaceuti-
cal analysis regarding selectivity and elimination of additive
interferences, which affect direct spectrophotometeric
methods. The literature is still poor in analytical assay meth-
ods based on kinetics for the determination of pravastatin in
dosage forms. Some speciﬁc advantages that the kinetic
methods possess are as follows (Perez-Bendito et al.,
1996):
– Simple and fast methods because some experimental steps
such as ﬁltration, extraction, etc. are avoided prior to
absorbance measurements.
– High selectivity since they involve the measurement of the
absorbance as a function of reaction time instead of mea-
suring the concrete absorbance value.
– Other active compounds present in the commercial dosage
forms may not interfere if they are resisting the chemical
reaction conditions established for the proposed kinetic
method.
– Colored and/or turbid sample background may possibly
not interfere with the determination process.
Therefore, there is a need for another kinetic approach to
estimate the drug in commercial dosage forms.
This paper describes a simple and sensitive kinetic spectro-
photometric method for the determination of pravastatin in
bulk and drug formulations. The method is based on the
reaction between pravastatin and 4-chloro-7-nitrobenzo-2-
oxa-1,3-diazole in acetone medium resulting in the formation
of yellow color, which absorbs maximally at 462 nm. The
absorbance increases with time and therefore, two calibration
procedures i.e., initial rate and ﬁxed time methods are
adopted for the determination of pravastatin in commercial
dosage forms.2. Experimental
2.1. Apparatus
A Jasco V-530 UV–vis spectrophotometer (Japan) with 1 cm
quartz cells was used for all absorbance measurements under
the following operating conditions: scan speed medium
(400 nm/min), scan range 375–550 nm and slit width 2 nm.
Spectra were automatically obtained by Jasco system software.
pH measurements were made with Consort C 830 (Belgium)
with combined glass pH electrode. A water bath shaker (Grant
Instruments, Cambridge Ltd., England) was used to control
the heating temperature for color development.
2.2. Materials and reagents
Pravastatin sodium, PVS, (C23H35O7Na, 446.52 g mol
1) was
supplied by CHEMLINE Healthcare (Lugano, Switzerland).
Its purity was found to be 99.3% according to the HPLC
method (British Pharmacopoeia, 2007). 4-Chloro-7-nitro-
benzo-2-oxa-1,3-diazole (NBD-Cl) was purchase from Aldrich
company. All other chemicals and reagents used were of ana-
lytical grade and all solutions were prepared with double dis-
tilled water.
2.3. Formulations
Pravastatin tablets supplied by Elsaad Pharma (Aleppo,
Syria), each tablet was labeled to contain pravastatin sodium
20 or 40 mg and pravastin tablets supplied by Rasha (Aleppo,
Syria), each tablet was labeled to contain pravastatin sodium
20 or 40 mg.
2.4. Solutions
Standard stock solution of pravastatin sodium of 0.5 mg mL1
was prepared in 100 mL volumetric ﬂask by dissolving the re-
quired amount of pravastatin sodium with 40 mL methanol,
the volume was then diluted to the mark with acetone. The
working standard solutions were freshly prepared by suitable
dilution of the stock solution with acetone. NBD-Cl 0.2%
solution was freshly prepared with acetone.
2.5. General procedures
2.5.1. Initial rate method
Aliquots of standard PVS solution (0.30–1.00 mL, 0.5 mg
mL1) were transferred into a series of 10 mL calibrated volu-
metric ﬂasks. Then 0.50 mL of NBD-Cl solution was added
and the volume was made up to the mark with acetone, mixed
well and heated on a water bath at 55 ± 2 C. After mixing,
the contents of each ﬂask were immediately transferred to
the spectrophotometric cell and the increase in absorbance
was recorded at 462 nm as a function of time between 0–
5 min against reagent blank treated similarly. The initial rate
of the reaction (m) at different concentrations was obtained
from the slope of the tangent to the absorbance–time curve.
The calibration curve was constructed by plotting the loga-
rithm of the initial rate (log m) vs the logarithm of the molar
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obtained either from the calibration graphs or the regression
equation.
2.5.2. Fixed time method
Aliquots of standard PVS solution (0.20–1.40 mL,
0.5 mg mL1) were transferred into a series of 10 mL cali-
brated volumetric ﬂasks. Then 0.50 mL of NBD-Cl solution
was added and the volume was made up to the mark with ace-
tone, mixed well and heated on a water bath at 55 ± 2 C for
25 min. After mixing, the contents of each ﬂask were immedi-
ately transferred to the spectrophotometric cell and the absor-
bance was recorded at 462 nm against reagent blank treated
similarly. The calibration curve was constructed by plotting
the absorbance against the ﬁnal concentration of the drug.
The amount of the drug in each sample was computed either
from calibration curve or regression equation.
2.6. Procedure for formulations
Twenty tablets containing PVS were weighed and ﬁnely pow-
dered. An amount of the powder equivalent to 25 mg of PVS
was dissolved in a 15 mL of methanol, mixed for about
5 min and then ﬁltered through Whatman ﬁlter paper number
40. The volume of ﬁltrate was adjusted to 20 mL with metha-
nol and diluted in a 50 mL volumetric ﬂask to the volume with
acetone to achieve a concentration of 0.5 mg mL1. The gen-
eral procedures were then followed in the concentration ranges
mentioned above.
3. Results and discussion
3.1. Absorption spectra
Several pharmaceutical compounds have been determined
through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-
diazole (NBD-Cl), such as, acetylcysteine, carbocisteine and
captopril (Taha et al., 2008; Haggag et al., 2008). In the pres-
ent study, PVS was found to react with NBD-Cl in acetone
medium at 55 ± 2 C producing a yellow color with maximum
absorbance at 462 nm (Fig. 1).Figure 1 Absorption spectra of (a) 50 lg mL1 PVS + 0.50 mL
NBD-Cl 0.2% against reagent blank, (b) reagent blank (NBD-Cl
0.2%) against acetone, and (c) 50 lg mL1 of PVS against
acetone.3.2. Optimization of reaction conditions
The optimum conditions for the development of method were
established by varying the parameters one at a time and keep-
ing the others ﬁxed and observing the effect produced on the
absorbance of the colored product. In order to establish exper-
imental conditions, the effect of various parameters such as
solvents, temperature, concentration of NBD-Cl and time of
heating were studied.
The pure drug is soluble in water, methanol, ethanol and ace-
tone. The colored product between PVS and NBD-Cl is not
formed in water medium and no problem was found when
PVS is dissolved in methanol, ethanol or acetone. Acetone was
found to be the best solvent for formation of colored product.
Whereas, in the application of the method, if a quantity of tab-
lets containing pravastatin sodium was dissolved in methanol,
ethanol or acetone, mixed, ﬁltered and then was diluted to the
volume with the solvent to achieve a required concentration of
PVS, the turbidwas formed in the solution. To resolve this prob-
lem, many solvents were used and 40% methanol/acetone (v/v)
was the best ratio to prepare the sample of formulations. So,
the same ratio of solvents was used to prepare the standard stock
solution and blank has the same ratio of solvents. The working
solutions were prepared by diluting very small volumes of stock
solution with acetone, so the ratio of methanol is negligible.
When using acidic, neutral or basic buffer media, such as
britton and borate buffers, reagent forms an orange yellow col-
or. This will decrease the absorbance of the sample solution
when using it as blank.
The effect of temperature on the reaction was studied in the
range of 20–65 C. About 55 C was found to be optimal for
maximum color development.
The most important factor affecting on the formation of
yellow product was the concentration of NBD-Cl. Fig. 2 shows
that 0.50 mL of 0.2% w/v NBD-Cl solution gave maximum
sensitivity. Increasing the volume of NBD-Cl leads to decrease
in the absorbance; this may be due to the high background
absorbance of the reagent.
The inﬂuence of the time of heating was investigated in the
range of 5–60 min. The experimental results show that heating
in the range 5–35 min gave the optimal values in kinetic studies.0.25
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Figure 2 Effect of concentration of NBD-Cl on the formation of
colored product PVS–NBD-Cl, [PVS] = 50 lg mL1 at 55 C for
10 min.
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Figure 3 Absorbance–time curve for the reaction of PVS with
NBD-Cl; [PVS] = 15–50 lg mL1.
Table 1 Values of rate constant k0.
[PVS] (M) k0 (S1)
302 S. Ashour, M. KhateebThe color product was stable for at least two days at room
temperature.
3.3. Quantitation methods
Because the intensity of the color increased with time (Fig. 3),
this was used as the basis for a useful kinetic method for the
determination of PVS. The initial rate, rate constant, variable
time (ﬁxed concentration or ﬁxed absorbance) and ﬁxed time
methods (Kopanica et al., 1983; Perez-Bendito and Silva,
1988) were tested and the most suitable analytical methods
were chosen regarding the applicability, sensitivity and the val-
ues of the intercept and correlation coefﬁcient (R2).
3.3.1. Initial rate method
The initial rate of reaction would follow a pseudo order rate
constant and obeyed the following rate equation:
m ¼ DA=Dt ¼ k0Cn
where m is the reaction rate, A is the absorbance, t is the mea-
suring time, k0 is the pseudo order rate constant, C is the con-
centration of the drug in mol L1 and n is the order of the
reaction. A calibration curve was constructed by plotting the
logarithm of the initial rate of reaction (log m) vs logarithm
of drug concentration (log C) which showed a linear relation-
ship over the concentration range of 15–50 lg mL1 (Fig. 4).y = 0.9457x + 0.8005
R2 = 0.9995 -3.6
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Figure 4 Calibration plot of logarithm rate of the reaction
against logarithm molar concentration of PVS for initial rate
method.The logarithmic form of the above equation was written as
follows:
log m ¼ logDA=Dt ¼ log k0 þ n logC
log m ¼ logDA=Dt ¼ 0:8005þ 0:9457 log½PVS ðR2 ¼ 0:9995Þ
Thus, k0 = 6.32 S1, and the reaction is the ﬁrst order
(n= 0.9457) with respect to PVS concentration. The limit of
detection (LOD) and limit of quantiﬁcation (LOQ) for initial
rate method were determined and were found to be 0.029
and 15 lg mL1, respectively.
3.3.2. Rate constant method
Graphs of log absorbance vs time for PVS concentration in the
range of 15–50 lg mL1 (3.36 · 105 to 11.19 · 105 M) were
plotted and all appeared to be rectilinear. Pseudo order rate
constant (k0) corresponding to different PVS concentrations
were calculated from the slopes multiplied by 2.303 and are
presented in Table 1. Regression of C vs k0 gave the following
equation:
k0 ¼ 0:00011 1:777C ðR2 ¼ 0:8779Þ3.3.3. Variable time method
Reaction rate data were recorded for different PVS concentra-
tions in the range 15–50 lg mL1. A preselected value of the
absorbance 0.34 was ﬁxed and the time was measured in the
seconds (Table 2). The reciprocal of time (1/t) vs the initial
concentration of PVS was plotted and the following equation
of calibration graph was obtained:
1=t ¼ 0:0032þ 59:536C ðR2 ¼ 0:9735Þ
The range of PVS concentrations giving the most satisfactory
results was limited 30–50 lg mL1 (6.72 · 105 to 11.19 ·
105 M).
3.3.4. Fixed time method
At preselected ﬁxed time, the absorbance of yellow colored
solution containing varying amounts of PVS was measured
at 55 C and 462 nm. Calibration graphs were constructed by
plotting the absorbance against the initial concentration of3.36 · 105 1.8 · 104
4.48 · 105 1.6 · 104
6.72 · 105 2.5 · 104
8.96 · 105 2.8 · 104
11.19 · 105 3.0 · 104
Table 2 Values of reciprocal time taken at ﬁxed absorbance
for the different rates of variable concentration of PVS at
constant concentrations of NBD-Cl.
[PVS] (M) 1/t (S1)
6.72 · 105 6.67 · 104
8.96 · 105 23.81 · 104
11.19 · 105 33.33 · 104
Table 6 Application of the proposed methods to the deter-
mination of PVS in dosage forms.
Sample %Recoverya ± SD
Proposed methods Oﬃcial method
Initial rate Fixed time
Pure PVS 100.53 ± 0.88 100.61 ± 0.74 99.40 ± 0.82
t-Value 1.36 1.84
F-Value 1.15 1.23
Pravastatin tablets (20 mg)
X± SDa 100.27 ± 0.60 100.35 ± 0.82 100.80 ± 0.76
t-Valueb 1.05 0.94 1.32
F-Valueb 1.60 1.16
Pravastatin tablets (40 mg)
X± SDa 100.32 ± 0.72 100.70 ± 1.05 101.05 ± 1.20
t-Valueb 0.99 1.52 1.28
F-Valueb 2.78 1.31
Pravastin tablets (20 mg)
X± SDa 100.67 ± 0.62 101.25 ± 1.14 99.89 ± 1.00
t-Valueb 2.50 2.44 1.79
F-Valueb 2.60 1.30
Pravastin tablets (40 mg)
X± SDa 101.34 ± 1.20 100.36 ± 0.95 100.52 ± 0.70
t-Valueb 2.49 0.83 1.81
F-Valueb 2.94 1.84
a Five independent analyses.
b Theoretical values for t and F-values at ﬁve degree of freedom
and 95% conﬁdence limit are (t= 2.776) and (F= 6.26).
Table 3 Regression equations for PVS at ﬁxed time and
55 C.
Time (min) Regression equation Correlation
coeﬃcient
Linear range
(lg mL1)
5 A= 0.0067C+ 0.0127 0.9993 15–50
10 A= 0.0102C  0.0244 0.9926 15–50
15 A= 0.0119C  0.0457 0.9991 15–60
25 A= 0.0138C  0.0699 0.9996 10–70
35 A= 0.0145C  0.0745 0.9982 10–70
A, absorbance; C, concentration.
Table 4 Analytical characteristics of the ﬁxed time (25 min)
method.
Parameters PVS
kmax (nm) 462
Beer’s law limit (lg mL1) 10–70
Molar absorptivity (L mol1 cm1) 0.49 · 104
Stoichiometric relationship, PVS:NBD-Cl 1:1
Logarithmic formation constant 6.02
Optimum photometric range (lg mL1) 20–50
Detection limit (lg mL1) 0.086
Limit of quantiﬁcation (lg mL1) 10
Sandell’s sensitivity (lg cm2 per 0.001
absorbance unit)
0.182
Regression equationa A= 0.0138C  0.0699
Correlation coeﬃcient, r 0.9996
a A= mC+ b, where C is the concentration in lg mL1 and A is
the absorbance
Table 5 Accuracy and precision for the determination of PVS
in bulk powder by the proposed methods (initial rate and ﬁxed
time).
Method PVS (lg mL1) Er% RSD (%) %Recovery ± SD
Taken Founda
Initial rate 20.00 20.06 0.30 1.05 100.30 ± 1.05
30.00 30.12 0.40 0.88 100.40 ± 0.88
40.00 40.18 0.45 0.81 100.45 ± 0.81
50.00 50.48 0.96 0.83 100.96 ± 0.84
Fixed time 10.00 10.13 1.30 1.38 101.30 ± 1.40
30.00 30.15 0.50 0.95 100.50 ± 0.95
50.00 50.21 0.42 0.35 100.42 ± 0.35
70.00 70.15 0.21 0.33 100.21 ± 0.33
a Average of six determinations.
Kinetic spectrophotometric determination of pravastatin in drug formulations 303PVS at ﬁxed time 5, 10, 15, 25 and 35 min. The regression
equations, correlation coefﬁcients and linear ranges are given
in (Table 3). Correlation coefﬁcient, intercept and slope values
for the calibration data calculated using the least squares
method (Miller and Miller, 1993).
It is clear that the slope increases with time and the most
acceptable values of the correlation coefﬁcient, linear range
and the intercept were obtained for a ﬁxed time of 25 min.
Therefore, the ﬁxed time of 25 min was utilized for the assay
of PVS concentration. The limit of detection (LOD) and limit
of quantiﬁcation (LOQ) for ﬁxed time (25 min) method were
determined and found to be 0.086 and 10 lg mL1, respec-
tively. For more accurate analysis, Ringbom optimum concen-
tration range was calculated to be 20–50 lg mL1. Table 4
shows the values of molar absorptivity, Sandell’s sensitivity
and some analytical characteristics for ﬁxed time (25 min)
method.
3.4. Stoichiometric relationship
The composition of colored product was determined by Job’s
method of continuous variation and mole-ratio method (Rose,
1964), for ﬁxed time (25 min) method. It is apparent from the
data that a molar ratio of 1:1 PVS to NBD-Cl.
As result, the most acceptable values of the correlation
coefﬁcients were obtained for an initial rate and ﬁxed time(25 min) methods. Thus, they were used for the determina-
tion of PVS in pure form and pharmaceutical formulations.
3.5. Analytical methods validation
The accuracy and precision of the proposed methods were car-
ried out by six determinations at four different concentrations.
Percentage relative standard deviation (RSD%) as precision
and percentage relative error (Er%) as accuracy of the sug-
gested methods were calculated. Table 5 shows the values of
relative standard deviations for different concentrations of
the PVS determined from the calibration curves. These results
of accuracy and precision show that the proposed methods
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Scheme 1 The proposed pathway of the reaction between PVS and NBD-Cl.
304 S. Ashour, M. Khateebhave good repeatability and reproducibility. The proposed
methods were found to be selective for the estimation of
PVS in the presence of various tablet excipients. For this
purpose, a powder blend using typical tablet excipients was
prepared along with the drug and then analyzed. The recover-
ies were not affected by the excipients and the excipients blend
did not show any absorption in the range of analysis.
3.6. Application to the pharmaceutical dosage forms
The performance of the proposed methods was assessed by
comparison with the pharmacopoeial method (British Pharma-
copoeia, 2007). Mean values were obtained with a Student’s
t- and F-tests at 95% conﬁdence limits for four degrees of free-
dom. The results showed comparable accuracy (t-test) and pre-
cision (F-test), since the calculated values of t- and F-tests were
less than the theoretical data.
The proposed procedures were applied to determine PVS in
its pharmaceutical formulations. The results in Table 6 indi-
cate the high accuracy and precision. As can be seen from Ta-
ble 6, the proposed methods have the advantages of being
virtually free from interferences by excipients such as glucose,
magnesium stearate, lactose, and starch or from common deg-
radation products. The results obtained were compared statis-
tically by the Student’s t-test (for accuracy) and the variance
ratio F-test (for precision) with those obtained by the ofﬁcial
method for the samples of the same batch (Table 6). The values
of t- and F-tests obtained at 95% conﬁdence level did not ex-
ceed the theoretical tabulated value indicating no signiﬁcant
difference between the methods compared.
3.7. Mechanism of the color reaction
A nitro group in NBD-Cl formula reduces the ring activity,
especially at para position, so the pair of electron at oxygen
in PVS (at meta position) bounds to para position in NBD-
Cl formula forming a colored product. Therefore, hydrochlo-
ride acid has been formed and the ring returns to its aromatic-
ity. The formation of HCl is not indicate that the reaction is
pH dependent, because the amount of HCl produced is very
small and diluted. The reaction mechanism is shown in
Scheme 1.
4. Conclusion
The proposed kinetic spectrophotometric methods for the
determination of PVS were simple, rapid, accurate and pre-cise and hence can be used for the routine analysis of PVS
in bulk and pharmaceutical formulations. 4-chloro-7-nitro-
benzo-2-oxa-1,3-diazole (NBD-Cl) was used as reagent in
acetone medium. The sample recoveries from all formula-
tions were in good agreement with their respective label
claims, which suggested non-interference of formulations
excipients in the estimation.
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